Extracellular Vesicles (EVs) as Tumor-Targeting Theranostic for Lung Cancer
Abstract
In this project, we aimed to create and test an Extracellular Vesicle (EV), and Super-Paramagnetic Iron Oxide Nanoparticle (SPION or NPs) based delivery system for carrying and delivering anticancer molecules (siRNA and chemo drug) to cancer sites in a tumor-targeted fashion. In the project's first year, we obtained all the required ACUC, IBC, and IRB approvals to conduct the study. We collected lung cancer and normal tissue from the resected lung of six NSCLC patients. We have successfully created organoids out of these tissues and validated them through IHC. Further in the study, we have isolated EV from these organoids and characterized them for making in vitro studies. Protocol for developing spheroids (3D cells) from established NSCLC cell lines viz. H1299 and A549 have also been done. As we continued to progress, we are now starting to develop patient-specific PDX mouse models from the tumor tissues collected from patients during this study. We also made anEV-NP-siRNA-B7H4 complex after screening and demonstrated its successful uptake and therapeutic effect in two NSCLC cell lines. The future work will include developing organoids and PDXs from tissues collected from VA hospital. Addition of targeting moiety and chemo. drug in EV-NP-siRNA complex and testing them for their theranostic properties in patient derived organoids and PDX models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2023
- Accession Number
- AD1206242
Entities
People
- Akhil Srivastava
Organizations
- University of Missouri